<DOC>
	<DOCNO>NCT01377285</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled clinical trial investigate renoprotective efficacy combine pentoxifylline ( PTX ) angiotensin receptor blocker ( valsartan ) , compare placebo valsartan 700 patient Chronic Kidney Disease ( CKD ) stag 3 4 . The effect cardiovascular comorbidity also observe . The observation period 3 year . The primary endpoint consist double serum creatinine , end stage renal disease ( ESRD ) , death cause . The secondary endpoint include change microalbuminuria proteinuria , serum urinary level TNF-a ( tumor necrosis factor-alpha ) , MCP-1 ( monocyte chemotactic protein ) , TGF-beta1 ( transform growth factor ) , collagens III ( amino terminal peptide procollagen III ) IV , fibronectin , urinary N-acetyl-beta-glucosaminidase , well serum fibrinogen high-sensitive CRP ( C reactive protein ) , development heart failure , nonfatal myocardial infarction , stroke transient ischemic attack .</brief_summary>
	<brief_title>Renoprotection Pentoxifylline Angiotensin Receptor Blocker Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description>This study multicenter placebo-controlled double-blind randomized clinical trial . The design scheme depict Figure 1 . ( see ) . At time screen , pentoxifylline-naïve participant must receive angiotensin receptor blocker ( ARB ) per day le 8 week stable renal function serum creatinine elevation &lt; 25 % precede 8 week . For patient take maximal dose angiotensin receptor blocker ( ARB ) 8 week , randomization start recruitment . For patient take submaximal , fix dose angiotensin receptor blocker ( ARB ) ≥ 8 week , good BP ( blood pressure ) , i.e. , ≤ 130/80 mmHg , randomization also start recruitment . However , patient take submaximal dose angiotensin receptor blocker ( ARB ) suboptimal BP , i.e. , ＞130/80 mmHg , patient recruit randomized dose angiotensin receptor blocker ( ARB ) fix ≥ 8 week , maximal dose angiotensin receptor blocker ( ARB ) administer ≥ 8 weeks.The recruit CKD ( Chronic kidney disease ) patient randomize receive pentoxifylline ( 400 mg twice day ) placebo ( one tablet twice day ) . Patients stage 3 CKD ( estimate GFR , eGFR30-59.9ml/min/1.73 m2 ) receive either pentoxifylline one tablet ( 400 mg ) twice day , placebo one tablet twice day.If patient still intolerant potential side effect , may withdraw study voluntarily . Patients stage 4 CKD ( estimate Glomerular filtration rate , eGFR15-29ml/min/1.73 m2 ) receive either pentoxifylline one tablet ( 400 mg ) per day , placebo one tablet per day . In patient develop potential side effect ( anorexia , epigastric distention , dizziness , headache ) test drug , may withdraw study voluntarily . If patient SBP ( systolic blood pressure ) &gt; 130 mmHg and/or DBP ( diastolic blood pressure ) &gt; 80 mmHg , necessary adjust antihypertensive drug . However , follow medication allow study : ACE ( angiotensin-converting-enzyme ) inhibitor ; phosphodiesterase inhibitor ( pentoxifylline ) ; direct vasodilator ( e.g. , hydralazine minoxidil ) , blunt decrease proteinuria , chronic immunosuppressive non-steroidal anti-inflammatory drug ( NSAID ) therapy . The randomization do stratification CKD ( Chronic kidney disease ) stag diabetic/non-diabetic status . CKD include stage 3 ( estimate GFR , eGFR30-59.9ml/min/1.73 m2 ) 4 ( estimate Glomerular filtration rate , eGFR15-29ml/min/1.73 m2 ) . CKD stage 3 divide 3A ( estimate Glomerular filtration rate , eGFR45-59ml/min/1.73 m2 ) 3B ( estimate Glomerular filtration rate , eGFR30-44ml/min/1.73 m2 ) accord recent guideline ( NICE clinical guideline 73 , Chronic kidney disease , September 2008 ) Two-arm random permute block randomization mixed block size 6 , 8 10 implement within stratum . Double-blind measure enforce participate hospital . And , extra effort make avoid noncompliance , miss data , loss follow-up trial . Patient 's renal function calculate Cockcroft-Gault simplify MDRD ( Modification Diet Renal Disease ) formula . All blood urine analysis perform Department Laboratory Medicine , NTUH ( National Taiwan University Hospital ) . Serum urine sample collect annually randomization , specimen allocate stored -70°C . Profibrotic inflammatory marker serum urinary level TNF-alpha , MCP-1 , TGF-beta1 , collagens III ( amino-terminal propeptide type III procollagen ) IV , fibronectin , urinary NAG , well serum fibrinogen high-sensitive CRP measure use commercially available kit . Genetic polymorphism MCP-1 fractalkine receptor also analyze evaluate association renal outcome .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Diabetic nondiabetic men woman 20 80 year age diagnose CKD stage 3 4 . The diabetic patient must type II diabetes mellitus ( DM ) overt proteinuria microalbuminuria twice within precede 6 month clinical exclusion nondiabetic kidney disease . Nondiabetic patient may may overt proteinuria ; proteinuric nondiabetic patient , proteinuria must present two occasion within precede 6 month . Renal replacement therapy expect within forthcoming 12 month . Currently angiotensin receptor blocker ( ARB ) therapy least 8 week , systolic blood pressure &lt; 150 mmHg , diastolic blood pressure &lt; 90 mmHg Renal function stable least 8 week ( fluctuation &lt; 25 % baseline ) time screen Type I DM patient Patients history allergy pentoxifylline methylxanthine derivative ( caffeine , theophylline ) take pentoxifylline dipyridamole treatment chronic disease precede 3 month screen . Patients take ACE inhibitor , renin inhibitor ( eg . Rasilez ) ; direct vasodilator ( e.g. , hydralazine minoxidil ) time screen Females nurse pregnancy , prepare pregnancy within next three year . Obstructive uropathy . Active gastrointestinal bleeding Active peptic ulcer , patient active bleed bleeding tendency patient antiplatelet anticoagulant therapy , except aspirin 100 mg , clopidogrel 75 mg . Unable stop chronic immunosuppressive therapy NSAID ; current use phosphodiesterase inhibitor pentoxifylline ( eg. , dipyridamole ) Congestive heart failure functional class III IV . Unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention , within past 3 month prior sign inform consent . Cerebral vascular disease within past 3 month prior sign inform consent . Retinal hemorrhage within past 3 month prior sign inform consent . Known suspected secondary hypertension ( e.g. , primary aldosteronism , renovascular hypertension , pheochromocytoma ) . Poor glycemic control ( HbA1c &gt; 8.5 % ) Liver cirrhosis hepatic dysfunction define abnormal liver function test Biliary obstructive disorder ( e.g. , cholestasis ) . Active malignancy infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>pentoxifylline</keyword>
	<keyword>angiotensin receptor blocker ( ARB )</keyword>
</DOC>